Search results
Showing 1 to 12 of 12 results for bimekizumab
Evidence-based recommendations on bimekizumab (Bimzelx) for treating axial spondyloarthritis in adults.
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active psoriatic arthritis in adults.
Bimekizumab for treating moderate to severe plaque psoriasis (TA723)
Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) (TA1028)
NICE is unable to make a recommendation about the use in the NHS of bimekizumab (Bimzelx) for treating moderate to severe hidradenitis suppurativa in adults. This is because UCB Pharma withdrew from the appraisal.
Show all sections
Sections for TA1028
Spesolimab for treating generalised pustular psoriasis flares [ID3963]
In development [GID-TA10871] Expected publication date: 18 June 2025
Spondyloarthritis in over 16s: diagnosis and management (NG65)
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
Awaiting development [GID-TA11150] Expected publication date: TBC
Find out more about NICE's new proportionate approach to technology appraisals
Discontinued [GID-TA11171]
Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]
Discontinued [GID-TA11151]
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.